Results 191 to 200 of about 539,865 (299)

Interleukin-22: a potential therapeutic target in atherosclerosis. [PDF]

Mol Med, 2021
Luo JW, Hu Y, Liu J, Yang H, Huang P.
europepmc   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

Advanced Science, EarlyView.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel, Anna‐Sophie Schlemmer, Andrea W. Eiken, Zachary W. Wagoner, Dennis Vöhringer, Lena Christ, Alex Dulovic, Patrick Marsall, Madeleine Fandrich, Eduardo J. S. Brás, Julia Marzi, Friederike Bärhold, Julia Philipp, Sven Becker, Lisa E. Wagar, Peter Loskill   +15 more
wiley   +1 more source

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

Advanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan, Xuelin Wang, Zhongyao Chen, Shuo Wang, Weining Gao, Ziyi Chen, Runyang Li, Cheng Hao, Lei Zhang, Qiongqiong Zhang, Ke Zhang, Mei Yu, Qian Liu, Jingxuan Wang, Huiping Li, Simpkins Fiona, Jing Liu, Qiang Liu, Peng Liu, Yawei Hu   +19 more
wiley   +1 more source

Interleukin-22 in Renal Protection and Its Pathological Role in Kidney Diseases. [PDF]

Front Immunol, 2022
Ma Q, Luan J, Bai Y, Xu C, Liu F, Chen B, Ju D, Xu H.   +7 more
europepmc   +1 more source

Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer <i>via</i> epidermal growth factor receptor/extracellular signal-regulated kinase pathway. [PDF]

World J Gastrointest Oncol
Ruan HX, Fang YL, Qin XN, Lin L.
europepmc   +1 more source

Interleukin-22 and interleukin-33 show up-regulated levels in the serum of patients with mild/moderate Coronavirus disease 2019. [PDF]

Beni Suef Univ J Basic Appl Sci, 2023
Majeed AY, Zulkafli NES, Ad'hiah AH.
europepmc   +1 more source

Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4‐Mediated Acute Hepatitis

Advanced Science, EarlyView.
This study identifies hepatocyte‐derived BDNF as an endogenous TLR4 antagonist that alleviates acute hepatitis. BDNF is downregulated in hepatocytes via REST‐mediated transcriptional repression during ALI/ALF. Mechanistically, BDNF binds to TLR4 on macrophages to suppress inflammation.
Weiwei Zhu, Yaqian Cui, Yongqiang Zhou, Yihui Zheng, Lijiang Huang, Leiming Jin, Qianhui Zhang, Pan Chen, Mengsha Lin, Jiaxi Ye, Yongqiang Xiong, Joo Young Huh, Xiang Hu, Xiaokun Li, Wu Luo, Guang Liang   +15 more
wiley   +1 more source

Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin. [PDF]

Diabetes Metab Syndr Obes
Sun P, Xiao Y, Dong Y, Feng Y, Zheng H, Liao X.   +5 more
europepmc   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source